Recombinant Human CEACAM5 / CD66e protein (Catalog#11077-H08H)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human CEACAM5 / CD66e (rh CEACAM5 / CD66e; Catalog#11077-H08H; NP_004354.2; Met1-Ala685) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
Source
Monoclonal Rabbit IgG Clone #061
Purification
Protein A
Formulation
PBS solution containing 0.5% BSA and 0.03%ProClin300
Concentration
5 μl/Test, 0.1 mg/ml
Conjugate
FITC
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze !
Synonyms: Anti-CD66e Antibody; Anti-CEA Antibody
Image / Experimental Information
Image 1 Description
Flow cytometric analysis of anti-Human CEACAM5 on HT29 cells.
CEACAM5, also known as CEA or CD66e, belongs to the large CEACAM subfamily of the immunoglobulin superfamily. CEACAM5 is expressed primarily by epithelial cells, and is synthesized as a glycoprotein with an MW of 180 kDa comprising 60% carbohydrate. CEACAM5 contains one Ig-like V-type domain at the N-terminus, followed by six Ig-like C2-type domains and a GPI anchor, and exists as a homodimer. CEACAM5 and CEACAM6 are overexpressed in many cancers and are associated with adhesion and invasion. CEACAM5 can mediate cell-cell adhesion through homotypic and heterotypic interactions. It functions as a homotypic intercellular adhesion molecule and serves as a widely used tumor marker, since it is expressed at higher levels in tumorous tissues than in corresponding normal tissues. CEACAM5 has also been shown to contribute to tumorigenicity by inhibiting cellular differentiation. In addition, CEACAM5 is identified as the host receptor for the Dr family of adhesins of E.Coli, and the binding of E.coli Dr adhesins leads to dissociation of the CEACAM5 homodimer.
Research Areas
Cancer Drug Targets
Tags
Cancer Immunotherapy
Immune Checkpoint
Immunotherapy
Targeted Therapy
References
Baczyska D, et al. (2003) The tumorigenic potential of human CX-1 colon adenocarcinoma cells depends on carcinoembryonic antigen (CEACAM5) expression. Cell Mol Biol Lett. 8(2): 471-86.
Blumenthal RD, et al. (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res. 65(19): 8809-17.
Liebig B, et al. (2005) Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. Cancer Lett. 223(1): 159-67.